• In March 2026, HealthEquity, Inc. reported that fourth-quarter revenue rose to US$334.59 million and net income to US$49.74 million, while full-year revenue reached US$1.31 billion with net income of US$215.2 million, alongside completion of a US$122.34 million share repurchase program.
• The company also raised its earnings outlook for the fiscal year ending January 2027, signaling management confidence by guiding to higher revenue, net income and diluted EPS.
• Next, we’ll examine how HealthEquity’s upgraded earnings guidance and completed share buyback may influence its longer-term investment narrative.

AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

HealthEquity Investment Narrative Recap

To own HealthEquity, I think you need to believe in long term growth in health savings accounts and the company’s ability to turn that into steadily rising earnings. The latest results and raised outlook reinforce the near term earnings catalyst, but they do not eliminate key risks such as dependence on interest income from custodial cash if rates weaken.

The most relevant update here is the higher fiscal 2027 earnings guidance, with HealthEquity now projecting revenue of US$1.405 billion to US$1.415 billion and net income of US$239 million to US$246 million. That outlook sits alongside a completed US$122.34 million buyback and keeps the focus on whether earnings can grow fast enough to support the current valuation catalyst.

Yet, despite this guidance upgrade, investors still need to watch the risk that a decline in interest rates could...

HealthEquity's narrative projects $1.6 billion revenue and $325.3 million earnings by 2028.

Uncover how HealthEquity's forecasts yield a $114.44 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$97 to US$167 per share, showing how far apart individual views can be. When you set those against HealthEquity’s upgraded earnings guidance, it underlines why you may want to compare several different expectations for how sustainable that growth could be.

Explore 3 other fair value estimates on HealthEquity - why the stock might be worth just $97.01!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your HealthEquity research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free HealthEquity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HealthEquity's overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.